Impact of Abcc2 (Mrp2) and Abcc3 (Mrp3) on the <i>In vivo</i> Elimination of Methotrexate and its Main Toxic Metabolite 7-hydroxymethotrexate

Maria L.H. Vlaming(Oncode Institute), Alfred H. Schinkel(Oncode Institute), Olaf van Tellingen(Dutch Cancer Society), Ronald P.J. Oude Elferink(Amsterdam University Medical Centers), Dirk R. de Waart, Els Wagenaar(The Netherlands Cancer Institute), Zeliha Pala(Istanbul University), Koen van de Wetering(Thomas Jefferson University), Anita van Esch
Clinical Cancer Research
December 15, 2008
10.1158/1078-0432.ccr-08-1609
Cited by 57

Related Papers

Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs
|Cell|1994|2.3k
Overcoming the blood–brain tumor barrier for effective glioblastoma treatment
|Drug Resistance Updates|2015|1k
Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins
|Proceedings of the National Academy of Sciences|1997|941
Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine
|Proceedings of the National Academy of Sciences|1997|884
Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C.
|PubMed|2002|688